LEO Pharma and the Parker Institute Partner to Advance Skin Disease Research
- LEO Pharma and the Parker Institute have entered a 3-year partnership with the objective to advance dermatology research.
- The collaboration will leverage the Parker Institute’s expertise in trial design, artificial intelligence, and SingleCell RNA sequencing and LEO Pharma’s global leadership in serving 90 million patients annually in medical dermatology to enhance understanding and treatment of skin diseases.
- This initiative reinforces LEO Pharma's commitment to unlock external innovation and drive standard of care improvement.
Ballerup, Denmark, 14 April 2025 – LEO Pharma and the Parker Institute at Copenhagen University Hospital have formed an academic partnership to advance research and innovation in medical dermatology. This collaboration aims to produce high-quality research that enhances disease understanding and benefits patients. Furthermore, it aims to discover molecules that could potentially be integrated into broader pharmaceutical research and development efforts.
“We are proud to partner with the Parker Institute in LEO Pharma’s first academic collaboration of this kind, strengthening ties to the academic world to foster innovative research”, said Dr. Jacob Pontoppidan Thyssen, Chief Scientific Officer & Executive Vice President at LEO Pharma. “While breakthroughs in skin science have improved treatment options, over 1000 skin diseases still lack effective treatments. This partnership is an important step in addressing these unmet needs. By combining our expertise, we aim to positively impact patients worldwide."
The Parker Institute excels in trial design and clinical testing across all phases, from early to late stages, and their expertise spans all forms of analysis. LEO Pharma aims to leverage the Parker Institute’s translational expertise to better understand immunophenotyping and how these insights apply to skin diseases. The Parker Institute’s proficiency in target evaluation and disease understanding will add significantly to LEO Pharma's research efforts.
Additionally, the Parker Institute's expertise in artificial intelligence (AI) and SingleCell RNA sequencing helps to understand how individual cells behave within the immune system. This advanced method, using AI, allows for a more detailed examination of single-cell data, giving a clearer understanding of how skin diseases work.
Dr. Lars Erik Kristensen, Vice President, Head of External Innovation at LEO Pharma, said, "Having spent several years at the Parker Institute prior to joining LEO Pharma, I have witnessed the dedication and expertise in their research efforts. By partnering with the Parker Institute, we see potential for unlocking new insights and strengthen our ability to advance the standard of care within medical dermatology. Earlier this year, LEO Pharma announced a collaboration with DEBRA Research, and this new partnership with the Parker Institute further reinforces our commitment to also leverage external innovation and use the world as our lab. By joining forces with such a recognized partner, we aim to advance our understanding of skin diseases, improve patient care, and potentially discover molecules that may be involved in wider pharmaceutical research and development initiatives later on."
Henning Bliddal, Head of the Parker Institute, added, "We are thrilled to collaborate with LEO Pharma, a global leader in medical dermatology. We have a shared commitment to advancing medical research and ultimately improving the lives of people suffering from skin diseases such as psoriasis and psoriatic arthritis, making LEO Pharma a strong partner for us.”
The partnership between LEO Pharma and the Parker Institute is a 3-year agreement.
Kontakter
For further information please contact:
Media: Jeppe Ilkjær, Head of Media Relations, LEO Pharma, mobile +45 3050 2014
Billeder
About Parker Institute
The Parker Institute is part of Copenhagen University Hospital at Bispebjerg and Frederiksberg. The Parker Institute strives, through research with focus on locomotory and related disorders, to improve the status of health in the population via prevention at all levels, increasing knowledge of disease mechanisms and diagnostics, and by creating evidence-based treatments. The activities include observations and register based research, analysis of literature, and diagnostic studies of patient-reported outcome measures, clinical tests, imaging with ultrasound and MRI, and biomechanical evaluation, as well as randomised clinical and population interventions. The Institute participates in creation of evidence-based prevention and medicine and in the development of new treatment strategies. The staff counts a broad range of health professionals and scientists, all dedicated to research into clinical advances for patients and disease prevention for the population. For more information, visit www.parker.dk.
About LEO Pharma
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma Presents New Late-Breaking Delgocitinib Cream Data For the Third Consecutive Year at AAD 20258.3.2025 17:45:38 CET | Pressemeddelelse
The post hoc analysis investigated treatment responses in a patient subgroup with moderate to severe Chronic Hand Eczema (CHE) treated with delgocitinib cream for 16 weeks in the DELTA 1 2 phase 3 trials.(1) Late-breaking presentation showcased that delgocitinib cream produced a deep, consistent and/or maintained response in a subgroup of patients with moderate to severe Chronic Hand Eczema (CHE).(1) Separate data presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting evaluated systemic exposure in patients following high use of delgocitinib cream to treat moderate to severe CHE.(2)
Liisa Hurme and Mark Levick elected to LEO Pharma’s Board of Directors5.3.2025 10:00:00 CET | Pressemeddelelse
At LEO Pharma’s Annual General Meeting 5 March 2025, Liisa Hurme, President and CEO of Orion Corporation, and Mark Levick, former EU medicines regulator and CEO of Alvotech, were elected as independent members of the Board of Directors. Liisa Hurme brings over 20 years of experience in the chemical and healthcare industries, with expertise in R&D, business development, global supply chains, and operations. She joined Orion Corporation in 1999 and became President and CEO in 2022. Liisa also chairs the Board at the Chemical Industry Federation of Finland and has served on various company and industry boards. She holds a doctorate in biochemistry from the University of Helsinki. Mark Levick is a former EU medicines regulator and CEO of Alvotech, a global biopharmaceutical company listed on the US NASDAQ. His expertise was gained through a successful career as a practicing specialist physician in Australia and the UK, before leading global R&D groups at GlaxoSmithKline and Novartis in the
LEO Pharma delivers double-digit revenue growth and strong progress for strategic transformation26.2.2025 09:00:00 CET | Pressemeddelelse
Ballerup, Denmark, 26 February, 2025 – LEO Pharma delivered another year of strong progress in 2024, with both sales growth and adjusted EBITDA margin ahead of the initial outlook for the year, putting the company on track to meet its profitability targets and to achieve its long-term strategic objectives. “2024 was a year of strong progress for LEO Pharma with double-digit growth in sales and another year of significantly improved EBITDA. A major highlight in 2024 was the approval and launch of our pioneering innovative topical Anzupgo® for chronic hand eczema (CHE). Additionally, we have strengthened our pipeline and successfully implemented efficiency initiatives set to substantially further improve our financial performance in 2025 and return LEO Pharma to a positive net result. With our innovative portfolio demonstrating significant commercial potential, and by maintaining financial discipline, delivering consistent high growth, and building an attractive pipeline, we are creating
DEBRA Research and LEO Pharma Announce Strategic Partnership to Advance Treatments for Rare Skin Diseases5.2.2025 09:00:00 CET | Pressemeddelelse
Partners form non-exclusive collaboration to expand research efforts and develop new treatments for Epidermolysis Bullosa (EB). The partnership leverages DEBRA Research’s focus on patient care and pharma experience and LEO Pharma’s extensive medical dermatology experience. Munich, Germany, and Ballerup, Denmark, 5 February 2025 – DEBRA Research GmbH, a non-profit organization dedicated to advancing research, advocacy, and support for those affected by Epidermolysis Bullosa (EB) and LEO Pharma, a global leader in medical dermatology, today announced a non-exclusive strategic partnership. This collaboration aims to enhance scouting capabilities and provide additional capacity to accelerate the development of life-changing therapies for EB. The partners are committed to driving transformative progress for EB patients and their families, and to deliver innovative medicines for this serious skin disease with no approved treatment options. “We are pleased to announce our non-exclusive partne
LEO Pharma Achieves Positive DELTA TEEN Trial Results with Anzupgo® (delgocitinib) Cream in Adolescents with Moderate to Severe Chronic Hand Eczema (CHE)4.2.2025 14:00:00 CET | Pressemeddelelse
The phase 3 clinical trial (DELTA TEEN) with Anzupgo® in adolescents, aged 12-17, with moderate to severe Chronic Hand Eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate, achieved primary and all key secondary endpoints compared to cream vehicle.(1) CHE can significantly affect the quality of life for adolescent patients.(2) There are currently no approved treatment options specifically indicated for moderate to severe CHE in the adolescent patient population.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum